MetaCap

Accuray (ARAY) vs SkyAI (SKYA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Accuray (ARAY) has outperformed SkyAI (SKYA) over the past year, gaining 97.6% versus a loss of 23.0%. SkyAI is the larger company by market cap ($7.8 million vs $6.2 million), about 1.3 times the size. Accuray converts more of its revenue into profit, with a net margin of -12.2% versus -138400.0%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ARAY+97.62%SKYA-22.97%
+281%+87%-107%
Nov 21, 20251 yearNov 20, 2026
ARAY-36.54%SKYA-99.98%
+35%-36%-106%
Apr 11, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ARAY versus SKYA key metrics
MetricARAYSKYA
Share price$2.08$2.18
Market cap$6.22M$7.82M
1-day change-2.12%-45.50%
YTD return+153.05%+7.39%
1-year return+97.62%-22.97%
5-year return-59.47%—
P/E ratio (TTM)—2.83
EPS (TTM)$-5.60$0.77
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$401.95M$204.12K
Revenue growth (YoY)-12.34%—
Net income (latest FY)$-49.19M$-282.50M
Gross margin27.73%-202.49%
Operating margin-6.58%-132145.49%
Net margin-12.24%-138400.02%
52-week high$45.20$4.39
52-week low$2.05$0.91
Distance from 52-week high-95.41%-50.34%
Analyst consensusnone—
Average volume201.35K1.74M
Shares outstanding3.00M3.59M
Employees80930
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ARAY has outperformed SKYA by 120.6 percentage points over the past year.
  • Accuray is more profitable, keeping -12.2 cents of every revenue dollar as net income versus -138400.0 cents for SkyAI.

About Accuray

ARAY stock →

Accuray Incorporated engages in the design, development, and sale of radiosurgery and radiation therapy systems for the treatment of tumors throughout the body in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.

Health Care · Medical/Dental Instruments · 809 employees

About SkyAI

SKYA stock →

SkyAI, Inc., a financial technology company with a Solana digital asset treasury that is building an agentic finance platform. It combines stablecoin rails with AI to deliver financial access, education, and actionable intelligence to the underbanked users in Asia, Latin America, and Africa.

Health Care · Medical/Dental Instruments · 30 employees

ARAY vs SKYA FAQ

Which is bigger, Accuray or SkyAI?

SkyAI (SKYA) is larger, with a market capitalization of $7.82M compared with $6.22M for Accuray (ARAY).

Which stock has performed better over the past year, ARAY or SKYA?

ARAY returned +97.62% over the past 12 months, compared with -22.97% for SKYA (price return, excluding dividends). Past performance does not predict future results.

Are Accuray and SkyAI in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons